Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Pharmacokinetics and central nervous system effects of the novel dual NK1 /NK3 receptor antagonist GSK1144814 in alcohol-intoxicated volunteers.

te Beek ET, Hay JL, Bullman JN, Burgess C, Nahon KJ, Klaassen ES, Gray FA, van Gerven JM.

Br J Clin Pharmacol. 2013 May;75(5):1328-39. doi: 10.1111/bcp.12004.

2.

Placebo- and amitriptyline-controlled evaluation of central nervous system effects of the NK1 receptor antagonist aprepitant and intravenous alcohol infusion at pseudo-steady state.

te Beek ET, Tatosian D, Majumdar A, Selverian D, Klaassen ES, Petty KJ, Gargano C, van Dyck K, McCrea J, Murphy G, van Gerven JM.

J Clin Pharmacol. 2013 Aug;53(8):846-56. doi: 10.1002/jcph.120. Epub 2013 Jun 18.

PMID:
23775877
3.

Pharmacokinetics and central nervous system effects of the novel dopamine D3 receptor antagonist GSK598809 and intravenous alcohol infusion at pseudo-steady state.

te Beek ET, Zoethout RW, Bani MS, Andorn A, Iavarone L, Klaassen ES, Fina P, van Gerven JM.

J Psychopharmacol. 2012 Feb;26(2):303-14. doi: 10.1177/0269881111431750. Epub 2012 Jan 4.

PMID:
22219221
4.

Central nervous system effects of the interaction between risperidone (single dose) and the 5-HT6 antagonist SB742457 (repeated doses) in healthy men.

Liem-Moolenaar M, Rad M, Zamuner S, Cohen AF, Lemme F, Franson KL, van Gerven JM, Pich EM.

Br J Clin Pharmacol. 2011 Jun;71(6):907-16. doi: 10.1111/j.1365-2125.2011.03902.x.

5.

Psychomotor and cognitive effects of a single oral dose of talnetant (SB223412) in healthy volunteers compared with placebo or haloperidol.

Liem-Moolenaar M, Gray FA, de Visser SJ, Franson KL, Schoemaker RC, Schmitt JA, Cohen AF, van Gerven JM.

J Psychopharmacol. 2010 Jan;24(1):73-82. doi: 10.1177/0269881108094524. Epub 2008 Aug 28.

PMID:
18755817
6.

The effects of a glycine reuptake inhibitor R231857 on the central nervous system and on scopolamine-induced impairments in cognitive and psychomotor function in healthy subjects.

Liem-Moolenaar M, Zoethout RW, de Boer P, Schmidt M, de Kam ML, Cohen AF, Franson KL, van Gerven JM.

J Psychopharmacol. 2010 Nov;24(11):1681-7. doi: 10.1177/0269881109105573. Epub 2009 Jul 31.

PMID:
19648218
7.

Dual orexin receptor antagonism by almorexant does not potentiate impairing effects of alcohol in humans.

Hoch M, Hay JL, Hoever P, de Kam ML, te Beek ET, van Gerven JM, Dingemanse J.

Eur Neuropsychopharmacol. 2013 Feb;23(2):107-17. doi: 10.1016/j.euroneuro.2012.04.012. Epub 2012 May 30.

PMID:
22658401
8.

The effects of the glycine reuptake inhibitor R213129 on the central nervous system and on scopolamine-induced impairments in psychomotor and cognitive function in healthy subjects.

Liem-Moolenaar M, Zoethout RW, de Boer P, Schmidt M, de Kam ML, Cohen AF, Franson KL, van Gerven JM.

J Psychopharmacol. 2010 Nov;24(11):1671-9. doi: 10.1177/0269881109106942. Epub 2010 Feb 8.

PMID:
20142308
9.

Characterising the plasma-target occupancy relationship of the neurokinin antagonist GSK1144814 with PET.

Ridler K, Gunn RN, Searle GE, Barletta J, Passchier J, Dixson L, Hallett WA, Ashworth S, Gray FA, Burgess C, Poggesi I, Bullman JN, Ratti E, Laruelle MA, Rabiner EA.

J Psychopharmacol. 2014 Mar;28(3):244-53. doi: 10.1177/0269881113517953. Epub 2014 Jan 15.

PMID:
24429221
10.

Central nervous system effects of haloperidol on THC in healthy male volunteers.

Liem-Moolenaar M, te Beek ET, de Kam ML, Franson KL, Kahn RS, Hijman R, Touw D, van Gerven JM.

J Psychopharmacol. 2010 Nov;24(11):1697-708. doi: 10.1177/0269881109358200. Epub 2010 Feb 8.

PMID:
20142302
11.

Design and synthesis of potential dual NK(1)/NK(3) receptor antagonists.

Hanessian S, Babonneau V, Boyer N, Mannoury la Cour C, Millan MJ, De Nanteuil G.

Bioorg Med Chem Lett. 2014 Jan 15;24(2):510-4. doi: 10.1016/j.bmcl.2013.12.033. Epub 2013 Dec 15.

PMID:
24374277
12.

Acute psychomotor effects of MDMA and ethanol (co-) administration over time in healthy volunteers.

Dumont GJ, Schoemaker RC, Touw DJ, Sweep FC, Buitelaar JK, van Gerven JM, Verkes RJ.

J Psychopharmacol. 2010 Feb;24(2):155-64. doi: 10.1177/0269881108099214. Epub 2009 Jan 22.

PMID:
19164498
13.

Evaluation of the cognitive, psychomotor and pharmacokinetic profiles of rupatadine, hydroxyzine and cetirizine, in combination with alcohol, in healthy volunteers.

Barbanoj MJ, García-Gea C, Antonijoan R, Izquierdo I, Donado E, Pérez I, Solans A, Jané F.

Hum Psychopharmacol. 2006 Jan;21(1):13-26.

PMID:
16389668
14.

Psychomotor effects, pharmacokinetics and safety of the orexin receptor antagonist suvorexant administered in combination with alcohol in healthy subjects.

Sun H, Yee KL, Gill S, Liu W, Li X, Panebianco D, Mangin E, Morrison D, McCrea J, Wagner JA, Troyer MD.

J Psychopharmacol. 2015 Nov;29(11):1159-69. doi: 10.1177/0269881115609015. Epub 2015 Oct 13. Erratum in: J Psychopharmacol. 2016 Jan;30(1):95.

PMID:
26464455
15.

Effects of sibutramine alone and with alcohol on cognitive function in healthy volunteers.

Wesnes KA, Garratt C, Wickens M, Gudgeon A, Oliver S.

Br J Clin Pharmacol. 2000 Feb;49(2):110-7.

16.

Pharmacokinetic-pharmacodynamic relationships of central nervous system effects of scopolamine in healthy subjects.

Liem-Moolenaar M, de Boer P, Timmers M, Schoemaker RC, van Hasselt JG, Schmidt S, van Gerven JM.

Br J Clin Pharmacol. 2011 Jun;71(6):886-98. doi: 10.1111/j.1365-2125.2011.03936.x.

18.

Pharmacokinetics and central nervous system effects of the novel dopamine D2 receptor antagonist JNJ-37822681.

te Beek ET, Moerland M, de Boer P, van Nueten L, de Kam ML, Burggraaf J, Cohen AF, van Gerven JM.

J Psychopharmacol. 2012 Aug;26(8):1119-27. doi: 10.1177/0269881111415733. Epub 2011 Sep 2.

PMID:
21890591
19.
20.

The sensitivity of pharmacodynamic tests for the central nervous system effects of drugs on the effects of sleep deprivation.

van Steveninck AL, van Berckel BN, Schoemaker RC, Breimer DD, van Gerven JM, Cohen AF.

J Psychopharmacol. 1999;13(1):10-7.

PMID:
10221355

Supplemental Content

Support Center